论文部分内容阅读
目的本研究在已构建好的柯萨奇病毒B3型(CVB3)疫苗pVP1的基础上,分别引入编码HMGB1不同结构域的质粒DNA,通过检测共免疫诱导的免疫应答强度,比较其各结构域介导的免疫增强作用。方法首先构建了编码HMGB1的不同结构域的质粒pHMGB1-A、B、C-box,分别与pVP1疫苗混合后肌注免疫小鼠,于末次免疫后10 d检测其诱导的特异性抗体和细胞免疫应答。结果与pVP1单独免疫组相比,pHMGB1-B box共免疫组可显著提高特异性血清IgG水平,同时也显著增加了脾脏IFN-γ+T的细胞数量;C-box仅显示出促进T细胞免疫的效应且程度较B-box小,对抗体水平无明显增强作用;A-box对抗体水平和细胞免疫应答的促进作用都不明显。结论 HMGB1不同结构域对病毒性心肌炎DNA疫苗诱导的体液和细胞免疫应答具有不同程度的增强效应,其中B-box可综合增强CVB3特异性体液和细胞免疫应答,C-box仅有促进T细胞应答效应,而对抗体水平无促进作用,A-box对抗体水平增加和细胞免疫应答的促进作用不明显。该研究不仅有助于深入了解HMGB1不同结构域的免疫佐剂效果差异,更为科学合理应用HMGB1增强免疫应答提供了一定的基础数据。
OBJECTIVE In this study, based on the constructed CVB3 vaccine pVP1, plasmid DNA encoding different domains of HMGB1 was introduced respectively, and the immune response induced by coimmunization was compared. The immune-enhancing effect. Methods Plasmid pHMGB1-A, B and C-box encoding different domains of HMGB1 were constructed and immunized intramuscularly with pVP1 vaccine respectively. The induced specific antibodies and cellular immunity were detected on the 10th day after the last immunization answer. Results Compared with the pVP1 alone immunization group, the pHMGB1-B box coimmunization group could significantly increase the level of serum IgG and increase the number of splenic IFN-γ + T cells. C-box showed only the promotion of T cell immunity Of the effect and the degree of B-box smaller, no significant increase in the level of antibodies; A-box antibody levels and the promotion of cellular immune response are not obvious. CONCLUSION: Different domains of HMGB1 enhance the humoral and cellular immune response induced by viral myocarditis DNA vaccine. B-box can enhance the specific humoral and cellular immune response of CVB3. C-box can only promote T cell response Effect, but no effect on antibody levels, A-box antibody levels and immune response to promote the role is not obvious. This study not only helps to understand the different effects of immune adjuvants in different domains of HMGB1, but also provides some basic data for the scientific and rational application of HMGB1 in enhancing immune response.